Financière de Tubize SA Overview
Pro stress-test →Financière de Tubize is a Belgian holding company established in 1928 that serves as a pure-play investment vehicle. The company's sole significant asset is a 36.27% stake in UCB, a major biopharmaceutical company focused on discovering and developing treatments for immune system and central nervous system disorders.
Strategic Profile
Pro stress-test →As a mono holding company, Financière de Tubize provides direct exposure to UCB's biopharmaceutical pipeline and global operations spanning multiple continents. The company benefits from UCB's specialization in high-value therapeutic areas including immunology and CNS treatment development, with R&D facilities across Belgium, Germany, Japan, the UK, and the US.
Competitive Landscape
Pro stress-test →As a holding company, Financière de Tubize competes in the passive investment vehicle space rather than operating in pharmaceutical markets directly. Its competitive positioning depends entirely on UCB's standing among biopharmaceutical peers focused on immunology and CNS therapeutics, competing with companies like Roche, Novartis, and other CNS/immunology specialists.
Industry Context
Financière de Tubize SA operates in Investment Holdings / Biopharmaceutical (via UCB subsidiary).
Key facts
Founded: 1928 · Headquarters: Brussels, Belgium · Market cap: $11.7B